Elicio Therapeutics, Inc. Common Stock ELTX

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

• GlobeNewswire Inc. 31 ago

  Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

  Elicio Therapeutics announced that its CEO Robert Connelly and Chief Scientific Officer Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The clinical-stage biotech company is developing next-generation immunotherapies for KRAS-driven cancers, with its lead program ELI-002 7P targeting the most common KRAS mutations found in approximately 25% of solid tumors.

  

• GlobeNewswire Inc. 2 jul

  Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

  Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech company, announced a registered direct offering of 4.38 million shares expected to raise approximately $15 million gross proceeds. The company plans to use the funds to support Phase 1 clinical development of ELI-002 7P in metastatic pancreatic cancer, pipeline advancement, and general corporate purposes. The offering is expected to close on or about July 6, 2026.

  

• GlobeNewswire Inc. 29 jun

  Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

  Elicio Therapeutics (ELTX), a clinical-stage biotech company developing immunotherapies for KRAS-driven cancers, was added to the Russell 2000 and Russell 3000 indexes as of June 26, 2026. The company is advancing its lead candidate ELI-002 7P, an off-the-shelf cancer immunotherapy targeting common KRAS mutations. However, the Phase 2 AMPLIFY-7P trial did not meet its primary endpoint of disease-free survival, prompting Elicio to refine its Phase 3 development strategy and initiate a Phase 1 study in metastatic pancreatic cancer.

  

• GlobeNewswire Inc. 15 jun

  Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

  Elicio Therapeutics announced that its Phase 2 AMPLIFY-7P study of ELI-002 7P did not meet the primary disease-free survival endpoint in the intent-to-treat population for adjuvant pancreatic cancer. However, post-hoc analyses showed promising results in the R0 resected patient subgroup (84% of enrolled patients) with a hazard ratio of 0.65 (p=0.048). Strong correlations between mutant KRAS-specific T cell responses and improved outcomes supported the drug's biological activity. The company plans to refine its Phase 3 strategy focusing on R0 resected patients with extended dosing, pending financing.